23431-48-3

Basic information

• Product Name: ALLYL P-TOLYL ETHER
• Synonyms: 4-Allyloxytoluene,Allyl p-Tolyl Ether;Allyl p-Tolyl Ether;ALLYL P-TOLYL ETHER;4-ALLYLOXYTOLUENE;allyltolylether;ally cresyl ether;p-Tolyl allyl ether
• CAS NO: 23431-48-3
• Molecular Formula: C₁₀H₁₂O
• Molecular Weight: 148.2
• Mol File: 23431-48-3.mol
• Article Data: 52

Chemical Properties

• Boiling Point: 214.5°C (estimate)
• Flash Point: 79.7 °C
• Appearance: /
• Density: 0.9719
• Vapor Pressure: 4.71E-08mmHg at 25°C
• Refractive Index: 1.5180-1.5200
• CAS DataBase Reference: ALLYL P-TOLYL ETHER(CAS DataBase Reference)
• NIST Chemistry Reference: ALLYL P-TOLYL ETHER(23431-48-3)
• EPA Substance Registry System: ALLYL P-TOLYL ETHER(23431-48-3)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 23431-48-3(Hazardous Substances Data)

Usage

General Description

Allyl p-tolyl ether, also known as allyl phenyl ether, is an organic compound with the chemical formula C10H12O. It is a clear, colorless liquid with a strong, sweet odor, and it is insoluble in water but soluble in organic solvents. Allyl p-tolyl ether is commonly used as a fragrance ingredient in perfumes and personal care products. It is also utilized in the manufacturing of pharmaceuticals, dyes, and other specialty chemicals. Additionally, it is a valuable intermediate in organic synthesis, serving as a precursor to various compounds such as allyl phenol and allyl diphenyl ether. However, allyl p-tolyl ether should be handled with caution as it is flammable and may cause irritation to the skin, eyes, and respiratory system upon exposure.

InChI:InChI=1/C16H18O4S/c1-3-7-13-10-11-14(19-2)12-16(13)20-21(17,18)15-8-5-4-6-9-15/h4-6,8-12H,3,7H2,1-2H3

Upstream product

• 106-44-5 p-cresol 
• 556-56-9 allyl iodid 
• 67-56-1 methanol 
• 1121-70-6 sodium 4-methylphenoxide 
• 106-95-6 allyl bromide 
• 71-43-2 benzene 
• 1746-13-0 allyl phenyl ether 
• 5954-75-6 2-vinylthiirane 
• 107-05-1 3-chloroprop-1-ene 
• 1072-43-1 propylene sulphide 
• 7450-04-6 1-((trimethylsilyl)methyl)-4-methylbenzene 
• 107-18-6 allyl alcohol 
• 67-64-1 acetone 
• 51896-41-4 cis-4-methylphenyl 1-propenyl ether 

Downstream Products

• 2186-24-5 cresyl-glicidyl ether 
• 6628-06-4 2-allyl-4-methylphenol 
• 99359-56-5 (2,3-dibromo-propyl)-p-tolyl ether 
• 58013-42-6 2-allyloxy-5-methylbenzyl chloride 
• 106-44-5 p-cresol 
• 26509-47-7 2,6-diallyl-4-methylphenol 
• 36895-25-7 3-phenyl-5-p-tolyloxymethyl-4,5-dihydro-isoxazole 
• 3199-35-7 2,5-dimethyl-2,3-dihydrobenzo[b]furan 
• 6698-70-0 (4-methylphenoxy)propan-2-one 
• 67845-46-9 2-(4-methylphenoxy)acetaldehyde 
• 114035-62-0 4-methyl-2-(morpholinomethyl)-6-allylphenol 
• 3722-74-5 3,4-Dihydro-6-methyl-2H-1-benzopyran 
• 500547-70-6 acetic acid-(2-allyl-4-methyl-phenyl ester) 
• 53889-94-4 4-methyl-2-(prop-1-enyl)phenol 

Relevant articles and documents

An SN1-type Reaction to Form the 1,2-Dioxepane Ring: Synthesis of 10,12-Peroxycalamenene

The synthesis of the sesquiterpene endoperoxide natural product 10,12-peroxycalamenene has been achieved. Featured transformations include an intramolecular Heck reaction to build the fused bicyclic core and a cobalt-catalyzed peroxidation to install the peroxide functional group. The final step involved an SN1-type ring closure catalyzed by DDQ to construct the 1,2-dioxepane ring.

Allylphenols as a new class of human 15-lipoxygenase-1 inhibitors

In this study, a series of mono- and diallylphenol derivative were designed, synthesized, and evaluated as potential human 15-lipoxygenase-1 (15-hLOX-1) inhibitors. Radical scavenging potency of the synthetic allylphenol derivatives was assessed and the results were in accordance with lipoxygenase (LOX) inhibition potency. It was found that the electronic natures of allyl moiety and para substituents play the main role in radical scavenging activity and subsequently LOX inhibition potency of the synthetic inhibitors. Among the synthetic compounds, 2,6-diallyl-4-(hexyloxy)phenol (42) and 2,6-diallyl-4-aminophenol (47) showed the best results for LOX inhibition (IC50 = 0.88 and 0.80 μM, respectively).

Preparation method 3 - phenoxybromopropane or analogue thereof

The invention discloses a preparation method of 3 -phenoxybromopropane or an analogue thereof, wherein 3 - phenoxybromopropane and an allyl compound thereof are obtained through substitution reaction and addition reaction so as to avoid the inconvenience of using gaseous hydrogen bromide, 2nd-step addition reaction is realized by using the brominated salt and the acid in situ, and the process is simple in operation. The condition is easy to control, the atom economy is good, the aspect of environmental impact is low pollution, zero emission accords with the current green chemical synthesis direction, and the cost is economic.

Profiling of LINS01 compounds at human dopamine D2 and D3 receptors

Abstract: Histamine and dopamine neuronal pathways display interesting overlapping in the CNS, especially in the limbic areas, making them very attractive to designing drugs with synergistic and/or additive effects. The roles of these systems to treat schizophrenia, drug addiction, Parkinson’s and Alzheimer’s diseases, among others are widely known. The LINS01 compounds were previously reported as histamine H3 receptor (H3R) antagonists and some of them are under evaluation in rodent memory models. Considering their pharmacological potential and similarities to literature dopamine D2 receptor (D2R) and dopamine D3 receptor (D3R) ligands, this work aimed to evaluate these compounds as ligands these receptors by using [3H]spiperone displacement assays. A set of 11 compounds containing the dihydrobenzofuranyl-piperazine core with substituents at 5-position of dihydrobenzofuran ring and at the piperazine nitrogen was examined. The compounds showed low to moderate affinities at both, D2R and D3R. N-Phenyl compounds LINS01005 (1d), LINS01011 (1h), LINS01012 (1i) and LINS01016 (1k) showed the highest affinities in the set to D3R (Ki 0.3–1.5 μM), indicating that N-phenylpiperazine moiety increases the affinity to this receptor subtype with some selectivity, since they showed lower affinities to D2R (Ki 1.3–5.5 μM). With the LINS01 compounds showing moderate binding affinity, new lead structures for optimization with regards to combined H3R and D2R/D3R-ligands are provided. Graphic abstract: Histamine and dopamine neuronal pathways display interesting overlapping in the CNS, and thus LINS01 compounds previously reported as histamine H3 receptor antagonists were evaluated as dopamine D2R and D3R ligands. The compounds showed micromolar affinities to both receptors[Figure not available: see fulltext.].